Professional Documents
Culture Documents
25224
25224
https://ebookmass.com/product/visual-imagery-and-human-rights-
practice-1st-ed-edition-sandra-ristovska/
https://ebookmass.com/product/advertising-imc-principles-and-
practice-tenth-global-edition-sandra-ernst-moriarty/
https://ebookmass.com/product/best-practices-in-school-
neuropsychology-guidelines-for-effective-practice-assessment-and-
evidence-based-intervention/
https://ebookmass.com/product/prostate-cancer-second-edition-
science-and-clinical-practice-jack-h-mydlo-md-facs/
Fundamentals of Nuclear Science and Engineering 3rd
Edition
https://ebookmass.com/product/fundamentals-of-nuclear-science-
and-engineering-3rd-edition/
https://ebookmass.com/product/scallops-biology-ecology-
aquaculture-and-fisheries-3rd-edition-sandra-e-shumway-and-g-jay-
parsons-eds/
https://ebookmass.com/product/counselling-skills-theory-research-
and-practice-3rd-ed-3rd-edition-john-mcleod/
https://ebookmass.com/product/addiction-medicine-science-and-
practice-2nd-edition-bankole-a-johnson/
https://ebookmass.com/product/casebook-of-clinical-
neuropsychology-ebook-pdf-version/
Neuropsychology
Neuropsychology
A Review of Science and Practice, III
Edited by
Sandra Koffler
Independent Practice
Philadelphia, Pennsylvania
E. Mark Mahone
Kennedy Krieger Institute
Johns Hopkins University School of Medicine
Baltimore, Maryland
Bernice A. Marcopulos
James Madison University
Harrisonburg, Virginia
University of Virginia
Charlottesville, Virginia
Douglas Johnson-Greene
Miller School of Medicine
University of Miami
Miami, Florida
Glenn Smith
Clinical and Health Psychology
University of Florida
Gainesville, Florida
1
1
Oxford University Press is a department of the University of Oxford. It furthers
the University’s objective of excellence in research, scholarship, and education
by publishing worldwide. Oxford is a registered trade mark of Oxford University
Press in the UK and certain other countries.
1 3 5 7 9 8 6 4 2
Index 277
v
PREFACE TO VOLUME III
This, the third volume of the series Neuropsychology: A Review of Science and Practice,
will provide the reader with timely and comprehensive reviews of the literature rel-
evant to clinical neuropsychology and related professions. Unique to this series, the
practitioner, investigator, and student will find that the chapters in Volume III con-
tribute to practice in its most broad definition: in the office, the laboratory, and the
classroom. The reviews in this volume provide resources for furthering ongoing re-
search, providing incentives for new studies and enhancing our value and service to
patients. Following is a brief summary of the chapters.
In Chapter 1, on cannabis and neurocognition, Pacheco-Colón, Duperrouzel, and
Gonzalez report their review of 30 neurobehavioral and neuroimaging studies. They
found that the non-acute effects of cannabis use are heterogeneous, but earlier onset
and heavier use are associated with memory and executive functioning deficits in
adults. The effects on adolescents are mixed. The authors conclude that in order to
further understand the long-term effects of cannabis use, confounding variables such
as cannabis composition and potency must be considered.
In Chapter 2, literature on arteriosclerosis, the small vessel disease of the brain,
is reviewed by Kaplan and Strainge for its association with age-related cognitive de-
cline, dementia, and possible late-life depression. The association of hypertension and
aging as risk factors for small vessel disease is reviewed, as well as the significant di-
agnostic studies that identify the associated brain lesions. Studies on the moderating
factor of cognitive reserve and the implications for clinical practice are presented.
Drs. Parsons and Kane, in Chapter 3, provide a state-of-t he-art technology review
of technology-enhanced assessment for the field of neuropsychology. The authors
consider advances in technology-enhanced assessment of specific conditions such
as attention deficit disorder, concussion, and cognitive aging. They discuss the dif-
ferent platforms (e.g., web-based vs. tablet-based) for administering more classic as-
sessment paradigms. Parsons and Kane explore how neuropsychology practitioners
may engage in telemedicine to expand access to clinical services. They further ex-
plore how technology can be deployed to enhance ecologically valid assessments.
This chapter is a primer on how ubiquitous technology is changing the status quo.
Chapter 4, on cross-cultural tests, reviews recent literature on cross-cultural neu-
ropsychological assessment with a focus on adults. Three methods for addressing this
issue are evaluated by Fernández and Marcopulos: (1) adapting existing tests through
language translation and norm development; (2) developing new tests specific to the
culture of interest; and (3) developing universal tests that can be adapted and used
with any language and culture.
vii
viii preface to volume iii
ix
x contributors
INTRODUCTION
Many patients presenting for neuropsychological assessments, in either the clinic or
the laboratory, have used cannabis at some point in their lives. During 2015, 44%
of Americans over 12 years of age reported ever having used the drug and 8.3%
endorsed past-month use (Center for Behavioral Health Statistics and Quality, 2016).
Among 12th graders, 45% have used cannabis and 23% have used in the past month
(Johnston, Miech, O’Malley, Bachman, & Schulenberg, 2016). Annual prevalence of
use rose from 24% during 1991 to 36% during 2016 among 12th graders. Concurrently,
public opinion toward legalization of cannabis has become more permissive. When
the Pew Research Center began surveying, in 1969, public opinion toward cannabis
legalization, 12% supported legalization, whereas 84% did not (Pew Research Center,
2016). A reversal occurred more recently, with 57% of Americans supporting and
37% opposing cannabis legalization during 2016. Consistent with these trends, 28
U.S. states have passed medical marijuana laws and 8 have legalized recreational use
for adults over the age of 21. These trends can also be observed around the world. For
instance, Uruguay legalized recreational use, while other countries such as Germany,
Canada, Argentina, Czech Republic, Italy, and Mexico have passed medical mari-
juana legislation. Also, in countries like the Netherlands and Spain, cannabis use is
decriminalized and largely tolerated.
Cannabis and its constituents are also the subject of research efforts focused on
medical applications. Results from studies examining the effectiveness of cannabis
as medicine suggest that it may be effective for treating nausea among patients with
cancer, anorexia among those with cancer or HIV, pain among patients with HIV or
multiple sclerosis (MS), and urinary dysfunction in those with MS (Borgelt, Franson,
Nussbaum, & Wang, 2013; Koppel et al., 2014). A recent meta-analysis examined
79 clinical trials and concluded that cannabinoids may be beneficial for nausea and
vomiting, pain reduction, and reduced spasticity (Whiting et al., 2015). If the trend for
medical cannabis continues to grow, one can expect additional patients presenting for
1
2 neuropsychology: a review of science and pr actice, iii
articles and meta- analyses are discussed first, followed by new cross- sectional
studies, and finally a review of new longitudinal studies. Cross-sectional studies con-
tinue to yield valuable insights into the effects of cannabis and have been valuable
in advancing research in this area. Yet, they have an important limitation: they pre-
clude making strong causal inferences between use of cannabis and declines in neu-
ropsychological functioning. They do not answer the question, “Does cannabis use
cause declines in neuropsychological functioning?” Studies that assess how changes
in cannabis use prospectively influence changes in neuropsychological functioning,
compare neuropsychological performance before and after onset of cannabis use, or
make use of co-t win designs are more apt for inferring causation. Thus, we review
these studies separately. Although such studies have been rare in the past, they are
now rapidly emerging. Each section is further subdivided into neurobehavioral and
neuroimaging studies. Finally, we briefly summarize some notable studies that do
not fall neatly into the aforementioned categories but that we thought would still be
of interest to readers. We then offer a summary and conclusion.
exposure. Specifically, there are clear acute impairments in inhibition, but the effects
on planning, problem solving, reasoning, and interference control are mixed (Broyd
et al., 2016).
Overall, findings on the effects of cannabis use on neurocognition appear heter-
ogeneous. As a possible explanation for this heterogeneity, Volkow et al. (2016) pos-
ited that the magnitude of neurocognitive impairment and the persistence of this
impairment after abstinence may depend on factors such as frequency and duration
of cannabis use, age of onset, and the length of the abstinence period. Furthermore,
the aforementioned reviews identify gaps in our knowledge and suggest areas for
future investigation, such as the neurocognitive effects of varying levels of cannabis
use at different stages of neural development (such as during adolescence), as well as
elucidating the effects of different types of cannabis (high vs. low potency; different
ratios of tetrahydrocannabinol [THC] to cannabidiol [CBD]) on neurocognition
(Broyd et al., 2016; Curran et al., 2016; Ganzer et al., 2016; Volkow et al., 2016).
Finally, Schoeler, Kambeitz, Behlke, Murray, and Bhattacharyya (2016) conducted
a meta-analysis investigating the effects of cannabis on memory performance in
healthy individuals and patients with psychosis. Across 88 studies comprising 7,697
healthy participants and 3,261 patients with psychosis, results revealed moderate ef-
fect sizes suggesting that cannabis use in healthy individuals was associated with sig-
nificantly impaired prospective memory, and small effect sizes for impaired global,
verbal immediate and delayed recall, and visual recognition. In those with psychosis,
however, there were small to moderate effect sizes suggesting that cannabis use was
associated with better global memory, visual immediate recall, and recognition rel-
ative to healthy cannabis users. Healthy cannabis users had higher depression scores
than age-matched non-users, and cannabis-using patients had lower depression levels
and were of a younger age than non-using patients. Thus, while cannabis appears to
have differential effects on memory for users with and without psychotic disorders,
these differences may have been due to the confounding influences of variables like
depression and age. Specifically, the lower level of depression and younger age of the
cannabis-using patients with psychosis may have attenuated the adverse effects of
cannabis on memory. Furthermore, longer duration of abstinence reduced cannabis
effects on memory across groups.
Neuroimaging Studies
Lorenzetti et al. (2016) conducted a review of 13 functional magnetic resonance im-
aging (fMRI) studies that involved tasks assessing working memory (e.g., N-back),
inhibition (e.g., go/no-go), and reward processing (e.g., monetary incentive delay
[MID]) in adolescents. All studies reviewed cross-sectionally compared healthy non-
using controls to cannabis user groups, with most samples smoking a mean of 400
lifetime occasions. Results suggested altered brain function in the frontal-parietal
network, a network thought to mediate cognitive control, particularly among heavier
users. Abnormalities reported across studies were heterogeneous across tasks, yet
hyperactivity in the posterior parietal region and medial prefrontal cortices was
5 Studies in Cannabis Use: Year in Review
suggested opposing effects of CBD and THC, with THC often inducing psychotic
symptoms and CBD acting as an antipsychotic and anxiolytic agent.
use (i.e., age at which they began using cannabis on a routine and consistent basis).
Even though both studies found that age of onset was important, future research
should examine whether age of first use or age of onset of regular use has a greater
impact on later outcomes and should be consistent in defining “regular” use in
order to facilitate better interpretation of findings (Crane, Schuster, Mermelstein,
& Gonzalez, 2015). Furthermore, although both studies used age 16 years as a
cutoff point between early and late onset, one classified age 16 onset as early and
the other as late onset.
Another set of cross-sectional studies from 2016 examined the effects of can-
nabis on various domains of neurocognition. For instance, Hirst, Young, Sodos,
Wickham, and Earleywine (2017) sought to explore whether the commonly reported
neurocognitive impairments in cannabis users could be due to a lack of effort put
forth during testing. They examined effort as a potential mediator of the association
between cannabis use and learning/memory performance in a sample of 62 young-
adult chronic cannabis users, defined as those using at least 4 days a week over the
past year. Participants completed a neurocognitive battery, which included tests
such as the CVLT-II and the Rey Complex Figure Test, as well as the Word Memory
Test, which assesses effort. Hirst et al. (2017) found that frequent cannabis users had
higher scores on the CVLT-II, thus failing to replicate previous research. However,
frequent cannabis use was associated with decreased effort, underscoring the impor-
tance of assessing effort with this population.
In order to examine the combined effects of cannabis and tobacco use on
neurocognition, Schuster, Mermelstein, and Hedeker (2016) employed an ecolog-
ical momentary assessment protocol in a sample of 287 community young adults.
The protocol involved a 7-d ay data-monitoring period in which participants used
handheld computers to complete assessments in real time. The devices provided
random prompts to the participants multiple times a day. Participants were also
instructed to initiate assessments immediately after smoking tobacco. During
both random and participant-initiated prompts, participants indicated whether
they had used cannabis or alcohol in the past hour. During these prompts,
participants also completed a brief spatial working memory task. Using a within-
subjects design, results indicated that working memory was poorer with cannabis
use (as well as alcohol use), but better with tobacco use. There was no interaction
between cannabis and tobacco use. Thus, tobacco use may compensate for the
adverse effects on working memory among young-adult cannabis users, as previ-
ously suggested in the context of episodic memory (Schuster, Crane, Mermelstein,
& Gonzalez, 2015).
Neuroimaging Studies
Jakabek, Yücel, Lorenzetti, and Solowij (2016) conducted a cross-sectional study
using diffusion tensor imaging (DTI) examining differences in white matter
structure in a sample of 56 regular cannabis users compared to 20 non-u sers.
White matter integrity was assessed by deriving fractional anisotropy (FA),
8 neuropsychology: a review of science and pr actice, iii
LONGITUDINAL STUDIES
Neurobehavioral Studies
In a prospective cohort study, Mokrysz et al. (2016) examined the association be-
tween adolescent cannabis use and IQ and educational outcomes in a sample of
2,235 adolescents from the Avon Longitudinal Study of Parents and Children. IQ
was assessed at ages 8 and 15, and educational performance data were collected at
ages 10–11 and 16. Users were categorized into five levels based on their cumulative
cannabis use frequency. Results indicated that cannabis users who had used can-
nabis at least 50 times by age 15 had lower IQ and poorer educational performance
at age 15 than those who had never used cannabis. However, after accounting for a
variety of potentially confounding variables, including pre-exposure IQ and educa-
tional performance, maternal and early life factors, childhood behavioral problems,
mental health, and adolescent use of other drugs, these associations were no longer
significant. Of these factors, cigarette use was the most influential in predicting edu-
cational outcome. These findings highlight the importance of accounting for poten-
tially confounding factors when examining the associations between cannabis use
and various outcomes. Of note, because the levels of cannabis use reported in this
sample were modest, it is possible that associations between cannabis use and IQ and
educational outcomes may manifest at higher levels of use.
Another longitudinal study, by Fishbein et al. (2016), examined the neurocognitive
characteristics associated with early onset of cannabis use. They followed a sample of
465 substance-naïve adolescents from a high-risk community from ages 10–12 at base-
line to ages 12–15. Participants underwent testing spanning multiple neurocognitive
domains, including IQ, memory, attention, decision-making, emotional perception,
and other executive functions. Results from a stepwise regression model revealed
significant associations between initiation of cannabis use and baseline performance
on neurocognitive tests, particularly on an Emotional Stroop Task, a task in which
children are asked to state the color that an emotional word (positive or negative)
is written in while disregarding the content of the word and which assesses cog-
nitive processing interference generated by emotional stimuli, as well as the Facial
Recognition Task (FACES). Specifically, misattribution of sad faces on the FACES
task and greater interference for positive than for neutral words on the Emotional
Stroop Task best predicted initiation of cannabis use. However, after controlling for
age, sex, and caregiver education, misattribution of sad faces on the FACES task was
the only significant predictor of initiation. The authors concluded that deficits in per-
ception of emotions may be a risk factor associated with early-onset cannabis use. It
is important to note, however, that this study focused on initiation of cannabis use;
more research is needed to understand the neurocognitive effects associated with
escalation in cannabis use.
Notably, Jackson et al. (2016) employed a co-t win design examining associations
between cannabis use and neurocognition using a sample of 3,066 twins from two
longitudinal cohorts. Twins from the Risk Factors for Antisocial Behavior (RFAB)
study underwent IQ testing at ages 9–10 and then again at 19–20, while those from
Another random document with
no related content on Scribd:
The Project Gutenberg eBook of Through
deserts and oases of central Asia
This ebook is for the use of anyone anywhere in the United
States and most other parts of the world at no cost and with
almost no restrictions whatsoever. You may copy it, give it away
or re-use it under the terms of the Project Gutenberg License
included with this ebook or online at www.gutenberg.org. If you
are not located in the United States, you will have to check the
laws of the country where you are located before using this
eBook.
Language: English
BY
AND
COPYRIGHT
PREFACE
Few works dealing with Chinese Turkestan and the Pamirs have
been published of late years, although the Heart of Asia, where the
empires of Great Britain, Russia and China meet, can never fail to
excite our interest. Furthermore, the great trade route which ran from
China to the Roman Empire lay across Chinese Turkestan, from
which remote land silk was introduced into Europe.
The present book has been written in two parts. The chapters
composing Part I., which describe the nine months’ journey in
deserts and oases, in mountains and plains, have been written by
my sister, while I am responsible for those dealing with the
geography, history, customs and other subjects.
We are indebted to Mr. Bohlin of the Swedish Mission in Chinese
Turkestan, and to Khan Sahib, Iftikhar Ahmad of the British
Consulate-General, Kashgar, for much assistance; and also to Dr. F.
W. Thomas, of the India Office, who has read through the historical
sketch.
A good deal of new material will be found in the various chapters,
and as far as possible the subjects so ably and exhaustively dealt
with by Sir Aurel Stein have been avoided.
To my sister belongs the honour of being the first Englishwoman to
cross the dangerous passes leading to and from the Pamirs and,
with the exception of Mrs. Littledale, to visit Khotan.
We greatly enjoyed the nine months we spent in Chinese Turkestan
and on the “Roof of the World,” and if we succeed in arousing the
interest of our readers in this old-world backwater of Asia, and at the
same time convey something of its distinctive charm, our ambitions
will be fulfilled.
P. M. SYKES.
CONTENTS
PART I
CHAPTER I
PAGE
CHAPTER II
Beyond the Tian Shan to Kashgar 18
CHAPTER III
Life at Kashgar 39
CHAPTER IV
Round about Kashgar 66
CHAPTER V
Olla Podrida 86
CHAPTER VI
On the Way to the Russian Pamirs 103
CHAPTER VII
The Roof of the World 129
CHAPTER VIII
The Aryans of Sarikol 148
CHAPTER IX
The Ancient City of Yarkand 175
CHAPTER X
Through the Desert to Khotan 191
CHAPTER XI
Khotan the Kingdom of Jade 209
PART II
CHAPTER XII
The Geography, Government and Commerce of Chinese
Turkestan 235
CHAPTER XIII
An Historical Sketch of Chinese Turkestan: The Early
Period 248
CHAPTER XIV
An Historical Sketch of Chinese Turkestan: The
Mediaeval and Later Periods 263
CHAPTER XV
An Historical Sketch of Chinese Turkestan: The
Modern Period 275
CHAPTER XVI
A Kashgar Farmer 300
CHAPTER XVII
Manners and Customs in Chinese Turkestan 308
CHAPTER XVIII
Stalking the Great Sheep of Marco Polo 324
INDEX 333
ILLUSTRATIONS
Note.—The illustrations, with one exception, are from reproductions of
photographs taken by the authors.
FACE PAGE
MAPS
Supplementary Sketch Map showing Country to
the East of Route Map 275
Map to illustrate Authors’ Routes (In pocket at end
of volume)
ERRATUM
Page 134, line 22, for “there was no sign of a division” read
“it was broken up into islands.”
PART I
CHAPTER I
ACROSS THE RUSSIAN EMPIRE IN WAR TIME
The cities are called Taskent[1] and Caskayre,[1] and the people that warre
against Taskent are called Cassaks[1] of the law of Mahomet, and they
which warre with the said countrey of Caskayre are called Kirghiz,
Gentiles and idolaters.—Anthony Jenkinson.